Blin O, Micallef J
Centre de Pharmacologie Clinique et d'Evaluatións Therapeutiques, H pital de la Timone, Marseille, France.
J Clin Psychiatry. 2001;62 Suppl 7:11-21.
Weight gain has been observed with many of the antipsychotics, including the atypical antipsychotics. The assessment of whether, and to what degree, a drug causes changes in body weight is not straightforward, since clinical studies performed during a drug development program are not designed to measure changes in body weight. Even when weight change data are obtained from adverse event data or from part of the vital signs measured during a study, assessment is not standardized. Nevertheless, evidence points to the fact that weight gain with the atypical antipsychotics is becoming an increasing problem. This review examines whether antipsychotic-associated weight gain, when it occurs, is associated with clinical outcome parameters.
许多抗精神病药物，包括非典型抗精神病药物，都已观察到有体重增加的现象。评估一种药物是否会导致体重变化以及变化程度并非易事，因为在药物研发项目中进行的临床研究并非旨在测量体重变化。即使从不良事件数据或研究期间测量的部分生命体征数据中获得了体重变化数据，评估也未标准化。然而，有证据表明非典型抗精神病药物导致的体重增加正成为一个日益严重的问题。本综述探讨抗精神病药物相关体重增加一旦发生，是否与临床结局参数相关。
